Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Confirmation of immunogenic consensus sequence HIV-1 T-cell epitopes in Bamako, Mali and Providence, Rhode Island
Human Vaccines, Volume 2, No. 3, Year 2006
Notification
URL copied to clipboard!
Description
The design of epitope-driven vaccines for HIV has been significantly hampered by concerns about conservation of vaccine epitopes across clades of HIV. In previous work, we have described a computer-driven method for a cross-clade HIV vaccine comprised of overlapping, highly conserved helper T-cell epitopes or "immunogenic consensus sequence epitopes" (ICS epitopes). Here, we evaluated and compared the immunogenicity of 20 ICS HIV epitopes in ELISpot assays performed using peripheral blood monocytes (PBMC) from HIV-infected donors in Providence, Rhode Island, USA and in Bamako, Mali, West Africa. Each core 9-mer HIV sequence contained in a given consensus peptide was conserved in at least 105 to as many as 2,250 individual HIV-1 strains. Nineteen of the 20 ICS epitopes (95%) were confirmed in ELISpot assays using PBMC obtained from 13 healthy, HIV-1 infected subjects in Providence, and thirteen of the epitopes (65%) were confirmed in ELISpot assays using PBMC derived from 42 discarded blood units obtained at the Central Blood Bank in Bamako. Twelve of the epitopes were confirmed in ELISpot assays performed both in Providence and Bamako. These data confirm the utility of bioinformatics tools to select and design novel vaccines containing "immunogenic consensus sequence" T-cell epitopes for a globally relevant vaccine against HIV; a similar approach may also be useful for any pathogen that exhibits high variability (influenza, HCV, or variola for example). An HIV vaccine containing these immunogenic consensus sequences is currently under development. ©2006 Landes Bioscience.
Authors & Co-Authors
Koita, Ousmane A.
Mali, Bamako
University of Bamako
Mali, Bamako
University of Bamako Faculty of Medicine, Pharmacy and Odonto-stomatology
Dabitao, Djeneba K.
Mali, Bamako
University of Bamako Faculty of Medicine, Pharmacy and Odonto-stomatology
Mahamadou, Ibrah
Mali, Bamako
University of Bamako
Tall, M.
Mali, Bamako
University of Bamako
Dao, Sounkalo M.
United States, Providence
Brown University
Tounkara, Anatole
Mali, Bamako
Centre National de Transfusion Sanguine
Guiteye, H.
Mali, Bamako
Centre National de Transfusion Sanguine
Noumsi, C.
Mali, Bamako
Centre National de Transfusion Sanguine
Thiero, Oumar
Mali, Bamako
University of Bamako Faculty of Medicine, Pharmacy and Odonto-stomatology
Kone, Mamady
Mali, Bamako
University of Bamako
Rivera, D.
United States, Providence
Epivax Incorporated
McMurry, J. A.
United States, Providence
Epivax Incorporated
Martin, William D.
United States, Providence
Epivax Incorporated
De Groot, Anne S.
United States, Providence
Brown University
United States, Providence
Epivax Incorporated
Statistics
Citations: 36
Authors: 14
Affiliations: 5
Identifiers
Doi:
10.4161/hv.2869
e-ISSN:
15548619
Research Areas
Infectious Diseases
Study Locations
Multi-countries
Mali